Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis

Vaccine

Volumn 26, Issue 11, 2008, Pages 1420-1431

  Smith, Kenneth J ^a   Zimmerman, Richard K ^a,b   Lin, Chyongchiou J ^a   Nowalk, Mary Patricia ^a   Ko, Feng Shou ^d   McEllistrem, M Catherine ^a   Roberts, Mark S ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c University of Pittsburgh   (United States)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Cost effectiveness analysis; Pneumococcal infections; Pneumococcal vaccines

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEROTYPE; STREPTOCOCCUS INFECTION; UNITED STATES; UNSPECIFIED SIDE EFFECT; VACCINATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; FEMALE; HEALTH CARE SURVEYS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MARKOV CHAINS; MENINGITIS, PNEUMOCOCCAL; MIDDLE AGED; MODELS, STATISTICAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; UNITED STATES;

EID: 39749203434     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.007     Document Type: Article

References (42)

1. Greene C.M., Kyaw M.H., Ray S.M., Schaffner W., Lynfield R., Barrett N.L., et al. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003. Clin Infect Dis 43 2 (2006) 141-150
2. Rodriguez-Barradas M.C., Musher D.M., Lahart C., Lacke C., Groover J., Watson D., et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 165 3 (1992) 553-556
3. Mufson M.A., Krause H.E., Schiffman G., and Hughey D.F. Pneumococcal antibody levels one decade after immunization of healthy adults. Am J Med Sci 293 5 (1987) 279-284
4. Jackson L.A., Benson P., Sneller V.P., Butler J.C., Thompson R.S., Chen R.T., et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 281 3 (1999) 243-248
5. Walker F.J., Singleton R.J., Bulkow L.R., Strikas R.A., and Butler J.C. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin Infect Dis 40 12 (2005) 1730-1735
6. Gardner P. A need to update and revise the pneumococcal vaccine recommendations for adults. Ann Intern Med 138 12 (2003) 999-1000
7. Ray G.T., Whitney C.G., Fireman B.H., Ciuryla V., and Black S.B. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 25 6 (2006) 494-501
8. McBean A.M., Jung K., and Hebert P.L. Decreasing invasive pneumococcal disease in the elderly: a state-level analysis. Vaccine 24 27-28 (2006) 5609-5614
9. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 16 (2005) 2043-2051
10. Melegaro A., and Edmunds W.J. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22 31-32 (2004) 4203-4214
11. Kyaw M.H., Lynfield R., Schaffner W., Craig A.S., Hadler J., Reingold A., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354 14 (2006) 1455-1463
12. Sisk J.E., Moskowitz A.J., Whang W., Lin J.D., Fedson D.S., McBean A.M., et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 278 16 (1997) 1333-1339
13. Sisk J.E., Whang W., Butler J.C., Sneller V.P., and Whitney C.G. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 138 12 (2003) 960-968
14. Melegaro A., and Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 19 4 (2004) 365-375
15. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
16. Ho K.K., Anderson K.M., Kannel W.B., Grossman W., and Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88 1 (1993) 107-115
17. Goldberg R.J., Larson M., and Levy D. Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham study. Arch Intern Med 156 5 (1996) 505-509
18. Kannel W.B., and Vokonas P.S. Demographics of the prevalence, incidence, and management of coronary heart disease in the elderly and in women. Ann Epidemiol 2 1-2 (1992) 5-14
19. Kannel W.B., D'Agostino R.B., Silbershatz H., Belanger A.J., Wilson P.W., and Levy D. Profile for estimating risk of heart failure. Arch Intern Med 159 11 (1999) 1197-1204
20. SEER age-specific cancer incidence, all sites. http://seer.cancer.gov/faststats/sites.php.
21. Fry A.M., Zell E.R., Schuchat A., Butler J.C., and Whitney C.G. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 21 3-4 (2002) 303-311
22. Self-reported pneumococcal vaccination coverage trends 1989-2006 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status, United States, National Health Interview Survey (NHIS). http://www.cdc.gov/flu/professionals/vaccination/pdf/pneumococcal-vaccinetrend.pdf.
23. Arias E. United States life tables, 2002. National vital statistics reports. vol. 53, no. 6. Hyattsville, Maryland: National Center for Health Statistics; 2004.
24. Wyrwich K.W., Fihn S.D., Tierney W.M., Kroenke K., Babu A.N., and Wolinsky F.D. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease. J Gen Intern Med 18 3 (2003) 196-202
25. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325 21 (1991) 1453-1460
26. Gold M.R., Franks P., McCoy K.I., and Fryback D.G. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 36 6 (1998) 778-792
27. CDC Vaccine Price List. http://www.cdc.gov/nip/vfc/cdc_vac_price_list.htm.
28. Pneumococcal vaccine (CPT 90732). http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM4109.pdf.
29. Medicare Physician Fee Schedule Look-up (CPT 90782). http://www.cms.hhs.gov/apps/pfslookup/.
30. Healthcare Cost & Utilization Project (HCUP). http://www.ahrq.gov/data/hcup/.
31. Annual Estimates of the Population by Five-Year Age Groups and Sex for the United States: April 1, 2000-July 1, 2006. http://www.census.gov/popest/national/asrh/NC-EST2006/NC-EST2006-01.xls.
32. Cantor S.B. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 14 3 (1994) 259-265
33. Laupacis A., Feeny D., Detsky A.S., and Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146 4 (1992) 473-481
34. Melegaro A., and Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 19 4 (2004) 353-363
35. Musher D.M., Phan H.M., Watson D.A., and Baughn R.E. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for Pneumococcal pneumonia. J Infect Dis 182 1 (2000) 158-167
36. Manoff S. Immunogenicity after revaccination with polysaccharide vaccine. 12th International Congress on Infectious Diseases. Lisbon, Portugal (2006)
37. Fedson D., and Musher D. Pneumococcal polysaccharide vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 4th ed. (2004), Saunders, Philadelphia, PA
38. O'Brien K.L., Hochman M., and Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?. Lancet Infect Dis 7 9 (2007) 597-606
39. Artz A.S., Ershler W.B., and Longo D.L. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 16 2 (2003) 308-318
40. Davidson M., Bulkow L.R., Grabman J., Parkinson A.J., Chamblee C., Williams W.W., et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 154 19 (1994) 2209-2214
41. Nuorti J.P., Butler J.C., Farley M.M., Harrison L.H., McGeer A., Kolczak M.S., et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance team. N Engl J Med 342 10 (2000) 681-689
42. Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C., et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 285 13 (2001) 1729-1735